fda catalysts

Incyte is getting sold like a one-drug story even as the second act gets closer

Incyte is still being traded like Jakafi is the whole story, and that framing is getting stale. Revenue grew 21% in Q1, Jakafi XR is already approved, and a September FDA catalyst gives the pipeline a much more investable shape than the stock seems to reflect.